Imunon, Inc. (NASDAQ:IMNN ) Q4 2024 Results Conference Call February 26, 2025 11:00 AM ET Company Participants Peter Vozzo - ICR Healthcare, IR Stacy Lindborg - President & Chief Executive Officer Douglas Faller - Chief Medical Officer David Gaiero - Interim Chief Financial Officer Michael Tardugno - Executive Chairman Khursheed Anwer - Chief Scientific Officer Conference Call Participants David Bautz - Zacks Small-Cap Research James Molloy - Alliance Global Partners Jason Kolbert - D. Boral Capital Kemp Dolliver - Brookline Capital Markets Operator Good morning.
IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer
LAWRENCEVILLE, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will report full year 2024 financial results before the opening of the U.S. financial markets on Thursday, February 27, 2025. The Company will host a conference call that same day beginning at 11:00 a.m. ET to discuss the results and provide a general business update.
Data reinforce dose-dependent mechanism with IMNN-001 100mg/m 2 dose associated with 20% increase in IL-12 levels compared to 79mg/m 2 dose
Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology and immunology
Based on more than six months of additional monitoring, data show continued improvement in overall survival (OS) in intent-to-treat (ITT) population of women newly diagnosed with advanced ovarian cancer
Imunon, Inc. (NASDAQ:IMNN ) Q3 2024 Earnings Conference Call November 7, 2024 11:00 AM ET Company Participants Kim Golodetz - Alliance Advisors IR Stacy Lindborg - President & Chief Executive Officer David Gaiero - Interim Chief Financial Officer Michael Tardugno - Executive Chairman Conference Call Participants David Bautz - Zacks Kemp Dolliver - Brookline Capital Markets James Molloy - Alliance Global Partners Operator Hello everyone. Good morning.
Conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J.
LAWRENCEVILLE, N.J., Oct. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) (the “Company”), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of (i) inducement stock options to purchase a total of 60,000 shares of the Company's common stock to one individual hired by Imunon during the fourth quarter of 2024 and (ii) inducement stock options to purchase a total of 50,000 shares of common stock to Susan Eylward, hired by Imunon as General Counsel and Secretary effective October 7, 2024 (collectively, the “Inducement Option Grants”). The Inducement Option Grants were approved in accordance with Nasdaq Listing Rule 5635(c)(4) and were made on October 7, 2024, as a material inducement to each employee's entry into employment with the Company.
September 18 th Event in New York City to Include a Review of the Opportunity for Investigational Therapy IMNN-001 (IL-12) to Treat Advanced Ovarian Cancer and Clinical Development Timeline